Catalent Capacity Update April 2025: Large Molecule Development

Catalent’s mammalian cell line engineering and biomanufacturing capabilities, utilizing single-use systems, provide the flexibility and scalability needed to support our customers' growth. At our state-of-the-art facility in Madison, WI, we offer a comprehensive range of integrated formulation and analytical services to address your most challenging development needs.

In this presentation, we will highlight the advancements in our latest cell line development technology platform, GPEx® Lightning. This innovative platform enables stable integration and expression of various protein modalities, including multispecifics and difficult-to-express proteins. By leveraging our proprietary non-viral gene insertion technology, GPEx® Lightning ensures rapid development timelines and high-yield production, making it an ideal solution for complex biologics. Additionally, the platform offers unparalleled flexibility and scalability, allowing seamless transition from early development to commercial manufacturing. Join us to discover how Catalent can accelerate your biologics development and bring your therapies to market faster.